Show simple item record

dc.contributor.authorChotiprasitsakul, D.
dc.contributor.authorHan, J.H.
dc.contributor.authorCosgrove, S.E.
dc.date.accessioned2019-06-05T18:28:17Z
dc.date.available2019-06-05T18:28:17Z
dc.date.issued2018
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85040634489&doi=10.1093%2fcid%2fcix767&partnerID=40&md5=617e9957fe3f94ba9f031f4a68fa052b
dc.identifier.urihttp://hdl.handle.net/10713/9438
dc.description.abstractBackground The recommended duration of antibiotic treatment for Enterobacteriaceae bloodstream infections is 7-14 days. We compared the outcomes of patients receiving short-course (6-10 days) vs prolonged-course (11-16 days) antibiotic therapy for Enterobacteriaceae bacteremia. Methods A retrospective cohort study was conducted at 3 medical centers and included patients with monomicrobial Enterobacteriaceae bacteremia treated with in vitro active therapy in the range of 6-16 days between 2008 and 2014. 1:1 nearest neighbor propensity score matching without replacement was performed prior to regression analysis to estimate the risk of all-cause mortality within 30 days after the end of antibiotic treatment comparing patients in the 2 treatment groups. Secondary outcomes included recurrent bloodstream infections, Clostridium difficile infections (CDI), and the emergence of multidrug-resistant gram-negative (MDRGN) bacteria, all within 30 days after the end of antibiotic therapy. Results There were 385 well-balanced matched pairs. The median duration of therapy in the short-course group and prolonged-course group was 8 days (interquartile range [IQR], 7-9 days) and 15 days (IQR, 13-15 days), respectively. No difference in mortality between the treatment groups was observed (adjusted hazard ratio [aHR], 1.00; 95% confidence interval [CI],.62-1.63). The odds of recurrent bloodstream infections and CDI were also similar. There was a trend toward a protective effect of short-course antibiotic therapy on the emergence of MDRGN bacteria (odds ratio, 0.59; 95% CI,.32-1.09; P =.09). Conclusions Short courses of antibiotic therapy yield similar clinical outcomes as prolonged courses of antibiotic therapy for Enterobacteriaceae bacteremia, and may protect against subsequent MDRGN bacteria. Copyright The Author(s) 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.en_US
dc.description.sponsorshipThis work was supported by the National Institute of Allergy and Infectious Diseases of the NIH (award number UM1AI104681), NIH grants K23-AI127935, K01-AI103028 ), and K24-AI079040.en_US
dc.description.urihttps://dx.doi.org/10.1093/cid/cix767en_US
dc.language.isoen-USen_US
dc.publisherOxford University Pressen_US
dc.relation.ispartofClinical Infectious Diseases
dc.subjectantibioticsen_US
dc.subjectduration of therapyen_US
dc.subjectgram-negative bacteremiaen_US
dc.subjectmultidrug-resistanten_US
dc.titleComparing the Outcomes of Adults with Enterobacteriaceae Bacteremia Receiving Short-Course Versus Prolonged-Course Antibiotic Therapy in a Multicenter, Propensity Score-Matched Cohorten_US
dc.typeArticleen_US
dc.identifier.doi10.1093/cid/cix767
dc.identifier.pmid29190320


This item appears in the following Collection(s)

Show simple item record